Spotlight on Myeloma 2024: Innovations and Insights from ASH
Stay up-to-date with the latest advancements in multiple myeloma treatment. Discover the benefits of integrating CD38 monoclonal antibodies and quadruplet regimens.
Stay up-to-date with the latest advancements in multiple myeloma treatment. Discover the benefits of integrating CD38 monoclonal antibodies and quadruplet regimens.
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
On April 30, 2024, during his first visit to Chile, Rafael Mariano Grossi, Director General of International Atomic Energy Agency (IAEA; Vienna, Austria) and Chile’s…
Health authorities in South Africa have promised to respond to the demands of protesters calling for the use of funds allocated for cancer treatment. On…
Speaking on behalf of researchers from 25 Spanish centres, Felipe Couñago (GenesisCare, Madrid, Spain) reported that moderate postoperative hypofractionated radiotherapy for patients with prostate cancer…
Lili Myers pays tribute to the late TV chef ahead of a mass motorbike ride to celebrate him.
Here, we summarize an article by Badar, et al. in Blood Cancer Journal comparing venetoclax + HMA with HMA-based therapy alone for newly diagnosed TP53-mutated…
Follow #ESMOBreast24 on Facebook, X (Twitter), LinkedIn, Instagram and YouTube.
A list of helpful resources compiled by the British Society for Haematology to support your wellbeing and your career, especially in the early stages.
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma (MM) is controversial. Between 2008 and 2014…
Amy Colada, University College London Hospital, London, UK, discusses the effectiveness of ambulatory care in place of inpatient care for patients undergoing stem cell transplantation…